<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664063</url>
  </required_header>
  <id_info>
    <org_study_id>ComboNTDs-PK</org_study_id>
    <nct_id>NCT03664063</nct_id>
  </id_info>
  <brief_title>PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )</brief_title>
  <official_title>A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) &amp; Azithromycin for Integrated Treatment of Neglected Tropical Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lihir Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lihir Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Pharmacokinetic and Pharmacodynamic study evaluating the safety of co-administering
      Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination
      treatment for LF. Individuals will be randomised to receive Azithromycin alone, IDA or
      combination therapy. Clinical and biochemical monitoring for safety will be undertaken. Drug
      levels will be measured in each of the three arms to assess whether combination therapy
      significantly alters drug levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug levels of Azithromycin, Ivermectin, Diethylcarbamazine, Albendazole</measure>
    <time_frame>4 Days</time_frame>
    <description>Plasma concentrations of Azithromycin, Ivermectin, Diethylcarbamize, Albendazole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Four days</time_frame>
    <description>Patients will undergo regular monitoring for the duration of the study - adverse events will be graded from 1 to 4 in line with the CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <condition>Yaws</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Azithromycin for Yaws</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard treatment for yaws alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDA for Lymphatic Filariasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard IDA (Ivermectin &amp; Diethylcarbamazine &amp; Albendazole) treatment for Lymphatic Filariasis alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy of Azithromycin for Yaws and IDA for LF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Treatment with Azithromycin single dose - weight based dosing max 2gm</description>
    <arm_group_label>Azithromycin for Yaws</arm_group_label>
    <arm_group_label>Combination Therapy of Azithromycin for Yaws and IDA for LF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Single dose of Albendazole weight based dosing
- 400mg</description>
    <arm_group_label>Combination Therapy of Azithromycin for Yaws and IDA for LF</arm_group_label>
    <arm_group_label>IDA for Lymphatic Filariasis</arm_group_label>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin weight based dosing - max 21mg</description>
    <arm_group_label>Combination Therapy of Azithromycin for Yaws and IDA for LF</arm_group_label>
    <arm_group_label>IDA for Lymphatic Filariasis</arm_group_label>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>Diethylcarbamazine weight based dosing - max 500mg</description>
    <arm_group_label>Combination Therapy of Azithromycin for Yaws and IDA for LF</arm_group_label>
    <arm_group_label>IDA for Lymphatic Filariasis</arm_group_label>
    <other_name>IDA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult aged 18-65

          -  Able to give informed consent

        Exclusion Criteria:

          -  Known chronic illness

          -  Hb &lt;7 at baseline

          -  Liver function or Creatinine * 1.5 Upper Limit of Normal

          -  Urinary tract infection at baseline

          -  Pregnancy (female participants only)

          -  Routine medications which interact with study drugs

          -  Lactose/Gluten intolerance

          -  Permanent disability impeding study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lihir Medical Centre</name>
      <address>
        <city>Londolovit</city>
        <state>New Ireland Province</state>
        <zip>034</zip>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lihir Medical Centre</investigator_affiliation>
    <investigator_full_name>Oriol Mitja</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

